FDA fast tracks former Leo Pharma eczema candidate
Union Therapeutics has been awarded fast track status by the FDA for its eczema candidate orismilast, which the biotech firm acquired from Leo Pharma.
by mikkel aabenhus hemmingsen, translated by catherine brett
Biotech company Union Therapeutics can take a shortcut onto the world's largest market for medical treatments, the US, after being awarded fast track status by the Food and Drug Administraion (FDA).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
